PHT-776 / Polymed Biopharma, Photys Therapeutics - LARVOL DELTA

Photys Therapeutics Enters into Exclusive License Agreement with Polymed for Phase 1-Ready IRAK4 Degrader, Furthering its Proximity-based Pipeline and Mission (GlobeNewswire) - "Photys Therapeutics...announced an exclusive in-license with Hangzhou Polymed Biopharmaceuticals, Inc., ('Polymed'), a novel drug discovery and development company based in Hangzhou, China and Cambridge, MA, for HPB-143 a phase 1-ready and potentially best-in-class IRAK4 degrader....Under the terms of the agreement, Polymed has granted Photys an exclusive global (ex-greater China and Southeast Asia) license to develop, manufacture, and commercialize HPB-143, which will be renamed to PHT-776. Financial terms of the agreement were not disclosed. Polymed previously submitted and received clearance from the FDA for the Investigational New Drug application (IND) for PHT-776....'We intend to initiate phase 1 studies later this year'."

IND • Licensing / partnership • New P1 trial • Atopic Dermatitis